Business Insider
My Markets Watchlist
Markets Stocks

Pfizer Inc. Stock , PFE

24.48 +0.17 +0.70%
03:59:59 PM EDT 6/11/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Tuesday 06/10/2025 the closing price of the Pfizer Inc. share was $24.31 on BTT. Compared to the opening price on Tuesday 06/10/2025 on BTT of $23.98, this is a gain of 1.36%. Pfizer Inc.'s market capitalization is $113.71 B by 5.69 B shares outstanding.
Is Pfizer stock a Buy, Sell or Hold? Pfizer stock has received a consensus rating of buy. The average rating score is A2 and is based on 25 buy ratings, 22 hold ratings, and 0 sell ratings.
What was the 52-week low for Pfizer stock? The low in the last 52 weeks of Pfizer stock was 20.92. According to the current price, Pfizer is 117.02% away from the 52-week low.
What was the 52-week high for Pfizer stock? The high in the last 52 weeks of Pfizer stock was 31.54. According to the current price, Pfizer is 77.63% away from the 52-week high.
What are analysts forecasts for Pfizer stock? The 47 analysts offering price forecasts for Pfizer have a median target of 42.98, with a high estimate of 75.00 and a low estimate of 24.00. The median estimate represents a 56.96 difference from the last price of 24.48.

Pfizer Stock Snapshot

24.40
Bid
200.00
Bid Size
24.41
Ask
460.00
Ask Size
6/11/2025
Date
3:59 PM
Time
739.00
Volume
24.31
Prev. Close
0.00
Open
139.24 B
Market Cap in USD
5.69 B
Number of Shares
5.69 B
Total Number of Shares
20.92
52 Week Low
31.54
52 Week High
24.48
1.69
Dividend in USD
6.37
Dividend Yield
18.83
P/E Ratio
99.82
Free Float in %
1.41
EPS in USD
15.56
Book Value per Share in USD
2.24
Cash Flow per Share in USD

Historical Prices for Pfizer

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Pfizer Analyst Data

Total Analysts: 47
Buy Ratings: 25 Neutral Ratings: 22 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 24.00 Median: 42.98 Highest: 75.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Pfizer Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
04/30/25 UBS
Maintained Hold $25
04/22/25 Cantor Fitzgerald
Maintained Hold $24
04/08/25 UBS
Maintained Hold $24
04/08/25 Goldman Sachs
Downgraded to Hold $25
03/18/25 Guggenheim
Maintained Buy
03/12/25 Guggenheim
Maintained Buy
02/10/25 Guggenheim
Maintained Buy $33
01/28/25 Citigroup Corp.
Maintained Hold $29
07/10/24 Barclays Capital
Maintained Hold $30
07/10/24 Cantor Fitzgerald
Maintained Buy $45
07/01/24 Cantor Fitzgerald
Maintained Buy $45
06/26/24 Cantor Fitzgerald
Maintained Buy $45
06/20/24 Cantor Fitzgerald
Maintained Buy $45
06/17/24 Cantor Fitzgerald
Maintained Buy $45
05/02/24 Morgan Stanley
Maintained Hold $29
05/02/24 BMO Capital Markets
Maintained Buy $36
04/18/24 Cantor Fitzgerald
Maintained Buy $45
04/15/24 Cantor Fitzgerald
Maintained Buy $45
04/05/24 Cantor Fitzgerald
Maintained Buy $45
04/01/24 Cantor Fitzgerald
Maintained Buy $45
03/22/24 Argus Research Company
Downgraded to Hold
03/04/24 Cantor Fitzgerald
Maintained Buy $45
03/01/24 Cantor Fitzgerald
Maintained Buy $45
02/23/24 Guggenheim
Maintained Buy $36
01/31/24 Cantor Fitzgerald
Maintained Buy $45
01/09/24 Cantor Fitzgerald
Maintained Buy $45
12/14/23 UBS
Maintained Hold $27
12/14/23 Barclays Capital
Maintained Hold $28
11/20/23 Cantor Fitzgerald
Maintained Buy $75
11/01/23 Barclays Capital
Maintained Hold $34
11/01/23 Morgan Stanley
Maintained Hold $37
10/20/23 UBS
Maintained Hold $34
10/17/23 Morgan Stanley
Maintained Hold $39
10/16/23 BMO Capital Markets
Maintained Buy $33
10/16/23 Citigroup Corp.
Maintained Hold $35
10/16/23 J.P. Morgan
Maintained Hold $34
10/16/23 Wells Fargo & Co
Maintained Hold $35
10/06/23 J.P. Morgan
Maintained Hold $36
10/02/23 Cantor Fitzgerald
Maintained Buy $75
09/18/23 Cantor Fitzgerald
Maintained Buy $75
09/05/23 Cantor Fitzgerald
Maintained Buy $75
08/30/23 Cantor Fitzgerald
Maintained Buy $75
08/22/23 Cantor Fitzgerald
Maintained Buy $75
08/02/23 Morgan Stanley
Maintained Hold $40
08/02/23 BMO Capital Markets
Maintained Buy $44
07/21/23 Morgan Stanley
Maintained Hold $42
07/11/23 Morgan Stanley
Maintained Hold $43
07/11/23 Barclays Capital
Maintained Hold $38
06/29/23 Credit Suisse
Downgraded to Hold $40
06/22/23 Cantor Fitzgerald
Maintained Buy $75

Pfizer Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 62,436 62,230 61,018 57,820 55,066
Dividend 1.71 1.74 1.78 1.67 1.77
Dividend Yield (in %) 6.97 % 7.12 % 7.26 % 6.81 % 7.23 %
EPS 3.00 3.09 3.09 2.77 2.47
P/E Ratio 8.16 7.93 7.93 8.85 9.91
EBIT 21,787 22,046 21,691 19,267 17,112
EBITDA 24,622 24,638 24,043 20,568 -
Net Profit 17,192 17,743 17,744 16,091 14,441
Net Profit Adjusted 17,192 17,743 17,744 16,014 14,441
Pre-Tax Profit 20,241 20,946 20,866 18,624 16,286
Pre-Tax Profit Reported - - 20,571 - -
EPS (Non-GAAP) ex. SOE 3.00 3.09 3.09 2.77 2.47
EPS (GAAP) 1.76 2.34 2.30 1.85 1.61
Gross Income 46,806 46,690 46,394 42,149 39,805
Cash Flow from Investing 755 -3,813 -3,609 -4,360 -4,228
Cash Flow from Operations 23,557 23,990 23,618 24,585 22,588
Cash Flow from Financing -14,082 -13,419 -14,462 -17,103 -17,326
Cash Flow per Share 3.18 - - 3.37 -
Free Cash Flow 19,660 18,870 19,643 18,489 20,822
Free Cash Flow per Share 3.11 2.73 2.81 - -
Book Value per Share 16.02 16.60 17.12 17.19 -
Net Debt 46,366 41,268 35,363 32,970 29,713
Research & Development Exp. 11,418 11,253 11,127 10,915 10,619
Capital Expenditure 2,676 2,550 2,436 2,409 2,346
Selling, General & Admin. Exp. 13,923 13,462 13,017 12,946 12,461
Shareholder’s Equity 93,068 97,722 101,533 112,640 115,520
Total Assets 208,964 207,676 206,503 196,668 190,880
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 13 13 20 20
Average Estimate - 0.566 USD 0.867 USD 3.001 USD 3.086 USD
Year Ago - 0.004 USD 0.789 USD 1.418 USD -
Publish Date - 8/5/2025 11/4/2025 - -
Revenue Estimates
No. of Analysts - 12 12 19 19
Average Estimate - 13,442 USD 17,168 USD 62,436 USD 62,230 USD
Year Ago - 13,283 USD 17,702 USD 63,627 USD -
Publish Date - 8/5/2025 11/4/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 63,627.00 58,496.00 100,330.00 81,288.00 41,908.00 51,750.00 53,647.00
Change of sales in % 8.77 -41.70 23.43 93.97 -19.02 -3.54 2.10
Gross profit on sales 41,846.00 29,283.00 62,090.00 46,875.00 29,843.00 37,011.00 37,639.00
Gross profit on sales change in % 42.90 -52.84 32.46 57.07 -19.37 -1.67 2.40
Operating income 16,483.00 4,235.00 37,549.00 20,793.00 9,018.00 14,117.00 15,289.00
Operating income change in % 289.21 -88.72 80.58 130.57 -36.12 -7.67 5.99
Income before tax 8,023.00 1,058.00 34,729.00 24,311.00 7,497.00 17,682.00 11,885.00
Income before tax change in % 658.32 -96.95 42.85 224.28 -57.60 48.78 -3.41
Income after tax 8,020.00 2,133.00 31,366.00 22,415.00 6,985.00 16,269.00 11,143.00
Income after tax change in % 276.00 -93.20 39.93 220.90 -57.07 46.00 -47.70

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 124,899.00 137,213.00 101,288.00 104,013.00 90,756.00 104,044.00 95,664.00
Long-term liabilities per share 14.45 15.84 10.53 10.91 11.65 12.06 11.16
Equity 88,497.00 89,288.00 95,917.00 77,463.00 63,473.00 63,445.00 63,758.00
Equity change in % -0.91 -6.95 23.91 22.08 0.18 -0.41 -11.08
Balance sheet total 213,396.00 226,501.00 197,205.00 181,476.00 154,229.00 167,489.00 159,422.00
Balance sheet total change in % -5.79 14.86 8.67 17.67 -7.92 5.06 -7.20

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 11.16 10.25 17.50 14.24 7.44 9.12 8.98
P/E ratio (year end quote, basic EPS) 18.83 76.67 9.37 15.22 21.56 13.66 23.39
P/E ratio (year end quote, diluted EPS) 18.83 76.67 9.37 15.22 21.56 13.66 23.39
Dividend yield in % 6.37 5.73 3.14 2.66 4.16 3.73 3.16
Equity ratio in % 41.47 39.42 48.64 42.68 41.16 37.88 39.99
Debt ratio in % 58.53 60.58 51.36 57.32 58.84 62.12 60.01

Pfizer Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
DAMICO JENNIFER B. 03/03/2025 2,500.00 11,850.00 25.93 Sell No
DAMICO JENNIFER B. 03/03/2025 5,583.00 14,350.00 n/a Buy No
DAMICO JENNIFER B. 02/26/2025 749.00 29,761.00 26.10 Sell No
Fonseca Lidia 02/26/2025 68,022.00 41,829.00 26.06 Sell No
Fonseca Lidia 02/26/2025 1,683.00 109,851.00 26.10 Sell No
BOURLA ALBERT 02/26/2025 545,855.00 367,589.00 26.06 Sell No
BOURLA ALBERT 02/26/2025 18,300.00 913,444.00 26.10 Sell No
Fonseca Lidia 02/26/2025 72,629.00 111,534.00 31.31 Buy No
BOURLA ALBERT 02/26/2025 582,823.00 931,744.00 31.31 Buy No
BOSHOFF CHRISTOFFEL 02/25/2025 4,872.00 155,100.00 26.42 Sell No
McDermott Michael 02/25/2025 3,220.00 73,994.00 26.42 Sell No
BOSHOFF CHRISTOFFEL 02/25/2025 9,687.00 159,972.00 n/a Buy No
BOSHOFF CHRISTOFFEL 02/23/2025 403.00 149,882.00 26.65 Sell No
DAMICO JENNIFER B. 02/22/2025 390.00 9,024.00 26.30 Sell No
LANKLER DOUGLAS M 02/21/2025 76,565.00 152,876.00 26.08 Sell No
LANKLER DOUGLAS M 02/21/2025 3,334.00 229,441.00 26.30 Sell No
SAHNI PAYAL 02/21/2025 11,343.00 25,188.00 26.08 Sell No
SAHNI PAYAL 02/21/2025 568.00 36,531.00 26.30 Sell No
SUSMAN SALLY 02/21/2025 56,715.00 165,684.00 26.08 Sell No
SUSMAN SALLY 02/21/2025 2,785.00 222,399.00 26.30 Sell No
BOURLA ALBERT 02/21/2025 212,680.00 348,921.00 26.08 Sell No
BOURLA ALBERT 02/21/2025 8,835.00 561,601.00 26.30 Sell No
McDermott Michael 02/21/2025 9,925.00 77,214.00 26.08 Sell No
McDermott Michael 02/21/2025 497.00 87,139.00 26.30 Sell No
DAMICO JENNIFER B. 02/21/2025 7,798.00 9,414.00 26.08 Sell No

Pfizer Dividend Calendar

Date Name Dividend *yield Currency
2024 Pfizer Inc. 1.69 6.37 USD
2023 Pfizer Inc. 1.65 5.73 USD
2022 Pfizer Inc. 1.61 3.14 USD
2021 Pfizer Inc. 1.57 2.66 USD
2020 Pfizer Inc. 1.53 4.16 USD
2019 Pfizer Inc. 1.46 3.73 USD
2018 Pfizer Inc. 1.38 3.16 USD
2017 Pfizer Inc. 1.30 3.59 USD
2016 Pfizer Inc. 1.22 3.76 USD
2015 Pfizer Inc. 1.14 3.53 USD
2014 Pfizer Inc. 1.06 3.40 USD
2013 Pfizer Inc. 0.98 3.20 USD
2012 Pfizer Inc. 0.90 3.59 USD
2011 Pfizer Inc. 0.82 3.79 USD
2010 Pfizer Inc. 0.74 4.23 USD
2009 Pfizer Inc. 0.66 3.63 USD
2008 Pfizer Inc. 1.28 7.23 USD
2007 Pfizer Inc. 1.16 5.10 USD
2006 Pfizer Inc. 0.96 3.71 USD
2005 Pfizer Inc. 0.76 3.26 USD
2004 Pfizer Inc. 0.68 2.53 USD
2003 Pfizer Inc. 0.60 1.70 USD
2002 Pfizer Inc. 0.52 1.70 USD
2001 Pfizer Inc. 0.44 1.10 USD
2000 Pfizer Inc. 0.36 0.78 USD
1999 Pfizer Inc. 0.31 - USD
*Yield of the Respective Date

Pfizer Calendar

Event Estimate Info Date
Earnings Report 0.566 USD Q2 2025 Earnings Release 08/05/2025
Earnings Report 0.867 USD Q3 2025 Earnings Release 11/04/2025
Earnings Report 0.719 USD Q4 2025 Earnings Release 02/03/2026
Earnings Report 0.687 USD Q1 2026 Earnings Release 05/05/2026

Pfizer Past Events

Event Actual EPS Info Date
Earnings Report 0.520 USD Q1 2025 Earnings Release 04/29/2025
Annual General Meeting 1.410 USD Annual General Meeting 04/24/2025
Earnings Report 0.070 USD Q4 2024 Earnings Release 02/04/2025
Earnings Report 0.780 USD Q3 2024 Earnings Release 10/29/2024
Earnings Report 0.010 USD Q2 2024 Earnings Release 07/30/2024
Earnings Report 0.550 USD Q1 2024 Earnings Release 05/01/2024
Annual General Meeting 0.370 USD Annual General Meeting 04/25/2024
Earnings Report -0.600 USD Q4 2023 Earnings Release 01/30/2024
Earnings Report -0.420 USD Q3 2023 Earnings Release 10/31/2023
Earnings Report 0.410 USD Q2 2023 Earnings Release 08/01/2023
Earnings Report 0.970 USD Q1 2023 Earnings Release 05/02/2023
Annual General Meeting 5.470 USD Annual General Meeting 04/27/2023
Earnings Report 0.870 USD Q4 2022 Earnings Release 01/31/2023
Earnings Report 1.510 USD Q3 2022 Earnings Release 11/01/2022
Earnings Report 1.730 USD Q2 2022 Earnings Release 07/28/2022
Earnings Report 1.370 USD Q1 2022 Earnings Release 05/03/2022
Annual General Meeting 3.850 USD Annual General Meeting 04/28/2022
Earnings Report 0.590 USD Q4 2021 Earnings Release 02/08/2022

Pfizer Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Pfizer Management

Name Job
Albert Bourla Chairman & Chief Executive Officer
Berta Rodriguez-Hervas Chief Artificial Intelligence & Analytics Officer
Aamir Malik Chief Commercial Officer-US & Executive VP
Sally Susman Chief Corporate Affairs Officer & Executive VP
David M. Denton Chief Financial Officer & Executive Vice President
James F List Chief Internal Medicine Officer
Alexandre de Germay Chief International Commercial Officer & EVP
Douglas M. Lankler Chief Legal Officer & Executive Vice President
Maria Rivas Chief Medical Affairs Officer
Patrizia A. Cavazzoni Chief Medical Officer & Executive Vice President
Luis Jodar Chief Medical Officer-Vaccines & Senior VP
Jeffrey Legos Chief Oncology Officer
Payal Sahni Becher Chief People Experience Officer & Executive VP
Lindsay Havern Chief of Staff & SVP-Executive Operations
Jeff Settleman Co-Chief Scientific Officer-Oncology
Mortimer Joseph Buckley Director
Rady A. Johnson EVP, Chief Compliance, Quality & Risk Officer
Michael Mcdermott EVP, Chief Global Supply & Quality Officer Officer
Denis Patrick Executive Director & Vice President-WRDM
Andrew Baum Executive VP, Chief Strategy & Innovation Officer
Lidia L. Fonseca Executive VP, Chief Technology & Digital Officer
Susan Rienow Global Chief Marketing Officer
Ronald Edward Blaylock Independent Director
Scott Gottlieb Independent Director
Dan R. Littman Independent Director
Joseph J. Echevarria Independent Director
Susan D. Desmond-Hellmann Independent Director
Susan J. Hockfield Independent Director
Suzanne Nora Johnson Independent Director
James C. Smith Independent Director
James Quincey Independent Director
Shantanu Narayen Lead Independent Director
Cyrus Russi Taraporevala Non-Executive Director
Chris Boshoff President-R&D & Chief Scientific Officer
William C. Sessa SVP & Chief Scientific Officer-Internal Medicine
Annaliesa Anderson SVP, Head-Vaccine Research & Development
Margaret M. Madden Secretary, Chief Governance Counsel & Senior VP
Jennifer B. Damico Senior Vice President & Controller
Bryan Supran Senior Vice President & Deputy General Counsel
Gordon Loh Senior Vice President-Corporate Audit
Matthew J. Leonard Senior Vice President-Global Access & Value
Barbara J. Dalton Vice President-Worldwide Business Development
John DeYoung Vice President-Worldwide Business Development